The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
The buzziest private companies are being sold to a select few as the universe of stocks everyone else can invest in shrinks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback